• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PROGESTERONE Drug Record

  • Summary
  • Interactions
  • Claims
  • PROGESTERONE chembl:CHEMBL103 Approved

    Alternate Names:

    NSC-64377
    CRINONE
    PROGESTA-CARE
    PROGESTASERT
    PROCHIEVE
    GESTEROL
    REGUMATE
    U 3672
    NSC-9704
    SYNGESTRONE
    SERENITY FOR WOMEN
    PROGESTIN
    CYCLOGEST
    UTROGESTAN
    PROGESTERONE
    LUTIGEST
    ENDOMETRIN
    PROMETRIUM
    PROGEFFIK
    FOLOGENON
    PREGN-4-ENE-3,20-DIONE
    CORLUVITE
    GESTORMONE
    LUTROMONE
    LUTOCUCLIN M
    LUTEOCRIN NORMALE
    GELBKÖRPERHORMON
    (S)-PREGN-4-EN-3,20-DIONE
    GESTEROL 50
    PROGESTÉRONE
    PROGESTOL
    4-PREGNENE-3,20-DIONE
    LUTEOPUR
    PROGESTOGEL
    PROLUTON
    GESTRON
    PREGNENE-3,20-DIONE
    PROMETRIUM®
    PROTORMONE
    PIAPONON
    DELTA(4)-PREGNENE-3,20-DIONE
    PROGESTERON
    GESTONE
    LUCORTEUM
    LUTOCYCLIN M
    LINGUSORBS
    CORPORIN
    PERCUTACRINE LUTEINIQUE
    LUTOGYL
    NALUTRON
    LUTIDON
    LUTEAL HORMONE
    CORPUS LUTEUM HORMONE
    LUTEOSAN
    CIDR
    17A-PROGESTERONE
    LUTEOHORMONE
    LUTOGYNON
    (1S,2R,10S,11S,14S,15S)-14-ACETYL-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
    SYNGESTRETS
    LUTEOSTAB
    PROGESTAN
    VITARRINE
    MEMBRETTES
    (8S,9S,10R,13S,14S,17S)-17-ETHANOYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
    LUTEOL
    CYCLOGESTERIN
    UTROGESTAN®
    LUTEOGAN
    LUTOCICLINA
    LUTEUM
    PROGESTEROL
    4-PREGNEN-3,20-DIONE
    GLANDUCORPIN
    LUTREN
    LUTOCYLOL
    GYNOLUTON
    BIO-LUTON
    PREGN-4-EN-3,20-DIONE
    PRONTOGEST
    AGOLUTIN
    PROGESTRONOL
    PROLUTIN
    PROGESTERONA
    PROGEKAN
    SYNTOLUTAN
    DELTA(SUP 4)-PREGNENE-3,20-DIONE
    D4-PREGNENE-3,20-DIONE
    (8S,9S,10R,13S,14S,17S)-17-ACETYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
    SYNOVEX S
    17Α-PROGESTERONE
    CRINONE PROGESTERONE GEL
    PERCUTACRINE
    LIPO-LUTIN
    FLAVOLUTAN
    PROGESTON
    LUTOCYLIN
    LUTOFORM
    LUCORTEUM SOL
    PROGESTONE
    GESTIRON
    LUTEOVIS
    (S)-4-PREGNENE-3,20-DIONE
    SYNGESTERONE
    ESTIMA
    17ALPHA-PROGESTERONE
    PROLIDON
    UTROGEST
    LUTEODYN
    DELALUTIN
    PRIMOLUT
    AKROLUTIN
    DURAPROGEN
    (S)-PROGESTERONE
    CURRETAB
    GYNOLUTONE
    BETA-PROGESTERONE
    LUTEX
    PROGESTERONUM
    MPA
    HORMOFLAVEINE
    PRANONE
    PREGNENEDIONE
    HORMOLUTON
    PROGESTOSOL
    GYNLUTIN
    PROGESTRON
    LUTOCYCLIN
    LUGESTERON
    CORLUTINA
    3,20-PREGNENE-4
    PROJESTAJECT
    METHYLPREGNONE
    COLPROSTERONE
    CORLUTIN
    PROLUTONE
    PROLETS
    GESTEROL 100
    pubchem.compound:5994
    chemidplus:57-83-0
    rxcui:8727
    chembl:CHEMBL103
    drugbank:00396

    Drug Info:

    FDA Approval approved
    Drug Class small molecule
    Drug Indications contraceptive
    Drug Indications for reducing the risk of pre-term birth for women with short cervix a mid-pregnancy
    Drug Indications for prevention of preterm delivery
    Drug Indications for symptomatic treatment of menopausal symptoms
    Drug Indications neuroprotectant for stroke victims
    Year of Approval approved before 1982
    Drug Class contraceptives
    (8 More Sources)

    Publications:

    Rupprecht et al., 1993, Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands., Eur. J. Pharmacol.
    Souque A et al., 1995, The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent., Endocrinology
    Quinkler M et al., 2002, Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor., Eur J Endocrinol
    Myles K et al., 1996, Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies., Am J Physiol
    Takagi et al., 2002, Bovine retained placenta: hormonal concentrations in fetal and maternal placenta., Placenta
    King et al., 2003, Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone., Biochem. Biophys. Res. Commun.
    Barten et al., 2003, Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood., J. Immunol. Methods
    Mitchell et al., 2002, Differential expression of activator protein-1 transcription factors in pregnant rat myometrium., Biol. Reprod.
    Vicent et al., 1998, Influence of calf serum on glucocorticoid-responses of certain progesterone derivatives., J. Steroid Biochem. Mol. Biol.
    Nakamura et al., 2001, Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil., Clin Transplant
    Labriola et al., 2003, Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells., Mol. Cell. Biol.
    Balañá et al., 1999, Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas., Oncogene
    Zagrodzki et al., 2007, The interaction between selenium status, sex hormones, and thyroid metabolism in adolescent girls in the luteal phase of their menstrual cycle., Biol Trace Elem Res
    Luconi et al., 1998, Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane., J. Clin. Endocrinol. Metab.
    Boonyaratanakornkit et al., 2007, The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle., Mol. Endocrinol.
    Gizard et al., 2006, TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone., Mol. Cell. Biol.
    Madauss et al., 2007, The evolution of progesterone receptor ligands., Med Res Rev
    Tranguch et al., 2006, Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation., Reprod. Biomed. Online
    Wu et al., 2006, Progesterone receptors activation after acute cocaine administration., Brain Res.
    Alvarez LD et al., 2011, Biological activity and ligand binding mode to the progesterone receptor of A-homo analogues of progesterone., Bioorg Med Chem
    Okada H et al., 2018, Decidualization of the human endometrium., Reprod Med Biol
    Ackland et al., 1997, Expression of Menkes disease gene in mammary carcinoma cells., Biochem. J.
    Seiler et al., 1995, Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist., Biochem. Pharmacol.
    Tosca et al., 2005, Adenosine 5'-monophosphate-activated protein kinase regulates progesterone secretion in rat granulosa cells., Endocrinology
    Zarghami et al., 1997, Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer., Br. J. Cancer
    Bentel JM et al., 1999, Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells., Mol Cell Endocrinol
    Yuan X et al., 2009, Mechanisms mediating androgen receptor reactivation after castration., Urol Oncol
    Miedema BW et al., 1992, Human gastric and jejunal transit and motility after Roux gastrojejunostomy., Gastroenterology
    Kumar et al., 2007, Type and duration of exogenous hormone use affects breast cancer histology., Ann. Surg. Oncol.
    Montero Girard et al., 2007, Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment., Breast Cancer Res.
    Yuri et al., Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats., In Vivo
    Lessey et al., 2006, Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women., Reprod. Biol. Endocrinol.
    Ghebeh et al., 2007, Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells., Int. J. Cancer
    Jayaraman A et al., 2009, Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones., J Neuroendocrinol
    Mohammed H et al., 2015, Progesterone receptor modulates ERα action in breast cancer., Nature
    Tessier C et al., 2000, Estrogen receptors alpha and beta in rat decidua cells: cell-specific expression and differential regulation by steroid hormones and prolactin., Endocrinology
    Désarnaud et al., 1998, Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells., J. Neurochem.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Zubiaur P et al., 2019, Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally., Adv Ther
    Musgrove et al., 2001, Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2., J. Biol. Chem.
    Swarbrick et al., 2000, Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells., Mol. Cell. Biol.
    Medina et al., 2004, Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells., J. Endocrinol.
    Stickeler et al., Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines., Oncol. Rep.
    Saitoh et al., 2005, Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells., Endocrinology
    Fu et al., 2008, Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton., PLoS ONE
    Kimura et al., 1991, The biological effects of macrophage-colony-stimulating factor induced by progestin on growth and differentiation of endometrial adenocarcinoma cells., Int. J. Cancer
    Prost-Avallet et al., 1991, In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma., J. Steroid Biochem. Mol. Biol.
    Kang et al., 1996, Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats., Biochem. Pharmacol.
    Kaur et al., 2007, Progesterone increases brain-derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants., J. Neurosci. Res.
    Adişen et al., 2006, The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis., J Eur Acad Dermatol Venereol
    Khurana et al., 1993, Receptor-mediated stimulatory effect of atrial natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on testosterone production in purified mouse Leydig cells: activation of cholesterol side-chain cleavage enzyme., Endocrinology
    Dorey et al., 1999, Regulation of human c-Abl tyrosine kinase activity in Xenopus oocytes and acceleration of progesterone-induced G2/M transition by oncogenic forms., Biol. Chem.
    Salatino et al., 2006, Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation., Oncogene
    Wu et al., 2005, Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells., Mol. Endocrinol.
    Cui et al., 2003, Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2., Oncogene
    McBean et al., 1997, In vivo estrogen regulation of epidermal growth factor receptor in human endometrium., J. Clin. Endocrinol. Metab.
    Attanasio et al., 2002, Immunomodulatory effects of estrogen and progesterone replacement in a nonhuman primate model., J. Clin. Immunol.
    Rodríguez-Cuenca et al., 2007, Expression of mitochondrial biogenesis-signaling factors in brown adipocytes is influenced specifically by 17beta-estradiol, testosterone, and progesterone., Am. J. Physiol. Endocrinol. Metab.
    Aoki et al., 2003, Effects of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells., J. Steroid Biochem. Mol. Biol.
    Syed et al., 2005, Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling., Oncogene
    Silberstein et al., 2002, Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth., Oncogene
    Melcangi et al., 1997, Astrocyte-neuron interactions in vitro: role of growth factors and steroids on LHRH dynamics., Brain Res. Bull.
    Ordi et al., 2006, Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation., Am. J. Reprod. Immunol.
    Schutzer et al., 1997, Lack of ovarian steroid hormone regulation of norepinephrine transporter mRNA expression in the non-human primate locus coeruleus., Psychoneuroendocrinology
    Guzeloglu-Kayisli et al., 2003, Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium., J. Clin. Endocrinol. Metab.
    Ordóñez et al., 2007, Insulin sensitivity in streptozotocin-induced diabetic rats treated with different doses of 17beta-oestradiol or progesterone., Exp. Physiol.
    Aydin et al., 1998, Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy., J Chemother
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Fujimoto et al., 1996, Requirement for transglutaminase in progesterone-induced decidualization of human endometrial stromal cells., Endocrinology
    Lima et al., 2008, Unique responses of midbrain CART neurons in macaques to ovarian steroids., Brain Res.
    Holst et al., 1983, Percutaneous oestrogen therapy opposed by lynestrenol or natural progesterone--effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein., Maturitas
    Dexheimer TS et al., 2009, 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors., J Med Chem
    Leo JC et al., 2004, Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells., Endocrinology
    Xu XF et al., 1990, Progestin binds to the glucocorticoid receptor and mediates antiglucocorticoid effect in rat adipose precursor cells., J Steroid Biochem
    Attardi et al., 2007, Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins., Am. J. Obstet. Gynecol.
    Strickler et al., 1982, 20 alpha-Hydroxysteroid dehydrogenase and 17 beta-estradiol dehydrogenase localize in cytosol of human term placenta., Am. J. Physiol.
    de la Llosa-Hermier et al., 1983, Inhibitory effect of ovine and human placental lactogens on progesterone catabolism in luteinized rat ovaries in vitro., Placenta
    Jones et al., 1982, Regulation of ovarian progestin production by epidermal growth factor in cultured rat granulosa cells., J. Biol. Chem.
    Rabe et al., 1985, Regulation of human placental progesterone synthesis in vitro by naturally occurring steroids., J. Steroid Biochem.
    Fukuda et al., 1986, Microsomal 20 alpha-hydroxysteroid dehydrogenase activity for progesterone in human placenta., Endocrinol. Jpn.
    Tsang et al., 1989, Influence of A23187 and dibutyryl cyclic AMP on progestagen production by rat granulosa cells in vitro., J. Reprod. Fertil.
    Wu et al., 1976, Luteotropic regulation of dispersed rat luteal cells in early pregnancy., Endocrinology
    Higaki et al., 2003, Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone., Chem. Biol. Interact.
  • PROGESTERONE   PAX2

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11850818


    Sources:
    NCI

  • PROGESTERONE   ATF3

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15674352


    Sources:
    NCI

  • PROGESTERONE   CR2

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9141535


    Sources:
    NCI

  • PROGESTERONE   CTSC

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17916955


    Sources:
    NCI

  • PROGESTERONE   PI3

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14521952


    Sources:
    NCI

  • PROGESTERONE   AKR1C1

    Interaction Score: 1.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6950669 6584862 6288675 3859707 3463506 2547059 179793 12604236


    Sources:
    NCI

  • PROGESTERONE   PMP22

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9751213


    Sources:
    NCI

  • PROGESTERONE   RNASEH2A

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12080023


    Sources:
    NCI

  • PROGESTERONE   EPHB1

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9279938


    Sources:
    NCI

  • PROGESTERONE   CD44

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11605071


    Sources:
    NCI

  • PROGESTERONE   NME2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15674352


    Sources:
    NCI

  • PROGESTERONE   PZP

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6410156


    Sources:
    NCI

  • PROGESTERONE   CARTPT

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18598674


    Sources:
    NCI

  • PROGESTERONE   PRKAB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16020477


    Sources:
    NCI

  • PROGESTERONE   TYMP

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12711006


    Sources:
    NCI

  • PROGESTERONE   ATP7A

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9359859


    Sources:
    NCI

  • PROGESTERONE   CD28

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11903384


    Sources:
    NCI

  • PROGESTERONE   NR3C2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name BHR-100
    Novel drug target Established target
    Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

    PMIDs:
    8282004 7588320 12039699 8928765


    Sources:
    TdgClinicalTrial

  • PROGESTERONE   PGR

    Interaction Score: 0.24

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name BHR-100
    Novel drug target Established target
    Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

    PMIDs:
    9506743 17138644 17015480 17013809 17169175 17109827 21315613 30013421


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND TTD

  • PROGESTERONE   TPM3

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549730


    Sources:
    NCI

  • PROGESTERONE   STS

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1751397


    Sources:
    NCI

  • PROGESTERONE   TAT

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9744518


    Sources:
    NCI

  • PROGESTERONE   NPPC

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8404664


    Sources:
    NCI

  • PROGESTERONE   SLC2A1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15350188


    Sources:
    NCI

  • PROGESTERONE   PROS1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Estradiol,Progesterone

    PMIDs:
    None found


    Sources:
    FDA

  • PROGESTERONE   CDKN1B

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11590147


    Sources:
    NCI

  • PROGESTERONE   OXTR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12061859


    Sources:
    NCI

  • PROGESTERONE   CP

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8619904


    Sources:
    NCI

  • PROGESTERONE   PROC

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Estradiol,Progesterone

    PMIDs:
    None found


    Sources:
    FDA

  • PROGESTERONE   NRG1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12529413 10597237


    Sources:
    NCI

  • PROGESTERONE   KLK3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9052414


    Sources:
    NCI

  • PROGESTERONE   FCGR3B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16635211


    Sources:
    NCI

  • PROGESTERONE   FAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14659903


    Sources:
    NCI

  • PROGESTERONE   CCND1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123159


    Sources:
    NCI

  • PROGESTERONE   TGM2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8603579


    Sources:
    NCI

  • PROGESTERONE   PLA2G1B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7872957


    Sources:
    NCI

  • PROGESTERONE   GFAP

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9370212


    Sources:
    NCI

  • PROGESTERONE   IL2RA

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12405159


    Sources:
    NCI

  • PROGESTERONE   CDK4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10713180


    Sources:
    NCI

  • PROGESTERONE   ROCK2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18665217


    Sources:
    NCI

  • PROGESTERONE   ESR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    negative modulator (inhibitory)
    agonist (activating)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase
    Novel drug target Established target
    Trial Name BHR-100

    PMIDs:
    17103262 17341305 17203775 17118173 17415709 19094096 26153859 11014241


    Sources:
    TdgClinicalTrial TEND

  • PROGESTERONE   CSF2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9822358


    Sources:
    NCI

  • PROGESTERONE   SLC2A4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17068109


    Sources:
    NCI

  • PROGESTERONE   PIK3CG

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16799639 15528272 14534541


    Sources:
    NCI

  • PROGESTERONE   SERPINC1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Estradiol,Progesterone

    PMIDs:
    None found


    Sources:
    FDA

  • PROGESTERONE   CSF1R

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1831804


    Sources:
    NCI

  • PROGESTERONE   PIK3CB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16954335


    Sources:
    NCI

  • PROGESTERONE   TDP1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19883083


    Sources:
    DTC

  • PROGESTERONE   NR3C1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:

    PMIDs:
    14617569 2214763 18060946


    Sources:
    DTC

  • PROGESTERONE   ABL1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10195429


    Sources:
    NCI

  • PROGESTERONE   PTEN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14557489


    Sources:
    NCI

  • PROGESTERONE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • PROGESTERONE   RXRA

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PROGESTERONE   RORC

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PROGESTERONE   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PROGESTERONE   TARDBP

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PROGESTERONE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 31482508


    Sources:
    DTC PharmGKB

  • PROGESTERONE   MAPK1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PROGESTERONE   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16684279


    Sources:
    NCI

  • PROGESTERONE   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROGESTERONE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    agonist (activating)
    potentiator

    Interaction Info:

    PMIDs:
    10509795 19111796 1397870


    Sources:
    DTC

  • PROGESTERONE   ABCB1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PROGESTERONE   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROGESTERONE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROGESTERONE   ALDH1A1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PROGESTERONE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PROGESTERONE   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: PROGESTERONE

    • Version: 01-August-2011

    Alternate Names:
    PROGESTERONE Primary Drug Name

    Drug Info:
    Drug Class contraceptives
    Year of Approval approved before 1982

    Publications:

  • TdgClinicalTrial: PROGESTIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications contraceptive
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • TdgClinicalTrial: PROGESTERONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications neuroprotectant for stroke victims
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: PROGESTERONE

    • Version: 14-September-2017

    Alternate Names:
    C777 NCI drug code

    Drug Info:

    Publications:
    Takagi et al., 2002, Bovine retained placenta: hormonal concentrations in fetal and maternal placenta., Placenta
    Mitchell et al., 2002, Differential expression of activator protein-1 transcription factors in pregnant rat myometrium., Biol. Reprod.
    Vicent et al., 1998, Influence of calf serum on glucocorticoid-responses of certain progesterone derivatives., J. Steroid Biochem. Mol. Biol.

  • NCI: PROGESTIN

    • Version: 14-September-2017

    Alternate Names:
    C777 NCI drug code

    Drug Info:

    Publications:
    Kimura et al., 1991, The biological effects of macrophage-colony-stimulating factor induced by progestin on growth and differentiation of endometrial adenocarcinoma cells., Int. J. Cancer
    Musgrove et al., 2001, Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2., J. Biol. Chem.
    Ordi et al., 2006, Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation., Am. J. Reprod. Immunol.

  • NCI: MPA

    • Version: 14-September-2017

    Alternate Names:
    C1155 NCI drug code
    C673 NCI drug code

    Drug Info:

    Publications:
    Seiler et al., 1995, Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist., Biochem. Pharmacol.
    Nakamura et al., 2001, Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil., Clin Transplant
    Aydin et al., 1998, Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy., J Chemother

  • DTC: PROGESTERONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL103 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Dexheimer TS et al., 2009, 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors., J Med Chem
    Alvarez LD et al., 2011, Biological activity and ligand binding mode to the progesterone receptor of A-homo analogues of progesterone., Bioorg Med Chem

  • PharmGKB: progesterone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Zubiaur P et al., 2019, Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally., Adv Ther

  • TTD: Progesterone

    • Version: 2020.06.01

    Alternate Names:
    D07BSQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL103

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Progesterone

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL103

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21